JP2024016237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016237A5 JP2024016237A5 JP2023192683A JP2023192683A JP2024016237A5 JP 2024016237 A5 JP2024016237 A5 JP 2024016237A5 JP 2023192683 A JP2023192683 A JP 2023192683A JP 2023192683 A JP2023192683 A JP 2023192683A JP 2024016237 A5 JP2024016237 A5 JP 2024016237A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- dose
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 22
- 102000003816 Interleukin-13 Human genes 0.000 claims 14
- 108090000176 Interleukin-13 Proteins 0.000 claims 14
- 102000004388 Interleukin-4 Human genes 0.000 claims 13
- 108090000978 Interleukin-4 Proteins 0.000 claims 13
- 230000037361 pathway Effects 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 208000019505 Deglutition disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 230000010339 dilation Effects 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000006440 Chemokine CCL26 Human genes 0.000 claims 1
- 108010083698 Chemokine CCL26 Proteins 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102000002171 Interleukin-4/interleukin-13 Human genes 0.000 claims 1
- 108050009538 Interleukin-4/interleukin-13 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940124624 oral corticosteroid Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229940125379 topical corticosteroid Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541242P | 2017-08-04 | 2017-08-04 | |
| US62/541,242 | 2017-08-04 | ||
| US201762561593P | 2017-09-21 | 2017-09-21 | |
| US62/561,593 | 2017-09-21 | ||
| EP18305252 | 2018-03-08 | ||
| EP18305252.1 | 2018-03-08 | ||
| PCT/US2018/045195 WO2019028367A1 (en) | 2017-08-04 | 2018-08-03 | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| JP2020505844A JP7417515B2 (ja) | 2017-08-04 | 2018-08-03 | 活動性好酸球性食道炎を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505844A Division JP7417515B2 (ja) | 2017-08-04 | 2018-08-03 | 活動性好酸球性食道炎を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016237A JP2024016237A (ja) | 2024-02-06 |
| JP2024016237A5 true JP2024016237A5 (enExample) | 2024-10-17 |
Family
ID=63113646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505844A Active JP7417515B2 (ja) | 2017-08-04 | 2018-08-03 | 活動性好酸球性食道炎を治療する方法 |
| JP2023192683A Pending JP2024016237A (ja) | 2017-08-04 | 2023-11-13 | 活動性好酸球性食道炎を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505844A Active JP7417515B2 (ja) | 2017-08-04 | 2018-08-03 | 活動性好酸球性食道炎を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3661551A1 (enExample) |
| JP (2) | JP7417515B2 (enExample) |
| KR (2) | KR20240152980A (enExample) |
| CN (1) | CN111032084A (enExample) |
| AU (2) | AU2018311981B2 (enExample) |
| CA (1) | CA3071528A1 (enExample) |
| IL (2) | IL315556A (enExample) |
| MA (1) | MA49744A (enExample) |
| MX (2) | MX2020001305A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250154267A2 (en) * | 2020-05-22 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| IL316470A (en) * | 2022-04-29 | 2024-12-01 | Akeso Biopharma Inc | Anti-human il-4ra antibody and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| AR098155A1 (es) * | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| AU2016231122A1 (en) * | 2015-03-11 | 2017-09-07 | Glaxosmithkline Intellectual Property Development Limited | TSLP binding proteins |
-
2018
- 2018-08-02 IL IL315556A patent/IL315556A/en unknown
- 2018-08-03 CA CA3071528A patent/CA3071528A1/en active Pending
- 2018-08-03 CN CN201880050334.6A patent/CN111032084A/zh active Pending
- 2018-08-03 KR KR1020247034392A patent/KR20240152980A/ko active Pending
- 2018-08-03 MX MX2020001305A patent/MX2020001305A/es unknown
- 2018-08-03 JP JP2020505844A patent/JP7417515B2/ja active Active
- 2018-08-03 EP EP18750578.9A patent/EP3661551A1/en active Pending
- 2018-08-03 AU AU2018311981A patent/AU2018311981B2/en active Active
- 2018-08-03 MA MA049744A patent/MA49744A/fr unknown
- 2018-08-03 KR KR1020207006346A patent/KR102719720B1/ko active Active
- 2018-08-03 IL IL272245A patent/IL272245B2/en unknown
-
2020
- 2020-01-31 MX MX2024012777A patent/MX2024012777A/es unknown
-
2023
- 2023-11-13 JP JP2023192683A patent/JP2024016237A/ja active Pending
-
2025
- 2025-02-12 AU AU2025200955A patent/AU2025200955A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016237A5 (enExample) | ||
| CN105392497B (zh) | 以il-4r抑制剂治疗嗜酸性食管炎的方法 | |
| Kim et al. | Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases | |
| JP2016523863A5 (enExample) | ||
| JP6306588B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| JP2022169718A5 (enExample) | ||
| RU2016101632A (ru) | Способы лечения полипоза носа путем введения антагониста il-4r | |
| JP2019531273A5 (enExample) | ||
| JP2022160685A5 (enExample) | ||
| JP2018158934A (ja) | 抗ｉｌ−５抗体を投与するための方法 | |
| JP2017535547A5 (enExample) | ||
| RU2015108073A (ru) | Способы лечения атопического дерматита с помощью антагониста il-4r | |
| JP2020500152A5 (enExample) | ||
| KR20140061403A (ko) | 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물 | |
| JP2020502261A5 (enExample) | ||
| JPWO2019222055A5 (enExample) | ||
| JPWO2021237110A5 (enExample) | ||
| JPWO2021026205A5 (enExample) | ||
| JP2020073525A5 (enExample) | ||
| JPWO2021195530A5 (enExample) | ||
| JP2020529434A5 (enExample) | ||
| HRP20191709T1 (hr) | Postupci liječenja nosne polipoze davanjem antagonista il-4r | |
| JPWO2019232070A5 (enExample) | ||
| Colice | Emerging therapeutic options for asthma | |
| RU2024121393A (ru) | Способы ослабления атопического марша посредством введения антагониста il-4/il-13 |